Scientific Sessions 2025  /  Hottest Clinical Trials in Valvular Heart Disease: Key Insights from Late-Breaking Studies  /  EVOLVED Trial: Early SAVR or TAVR in Severe Asymptomatic Aortic Stenosis with Left Ventricular Fibrosis.
Logo

American Heart Association

  33
  0

Final ID:

EVOLVED Trial: Early SAVR or TAVR in Severe Asymptomatic Aortic Stenosis with Left Ventricular Fibrosis.

  • Mehran, Roxana  ( Icahn School of Med. at Mount Sinai , New York , New York , United States )
  • Prendergast, Bernard  ( St Thomas' Hospital , London , United Kingdom )
  • Loganath, Krithika  ( University of Edinburgh , Edinburgh , Scotland , United Kingdom )
  • Dweck, Marc  ( University of Edinburgh , Edinburgh , Scotland , United Kingdom )
    • Author Disclosures:
    Roxana Mehran: DO have relevant financial relationships ; Research Funding (PI or named investigator):Abbott, Alleviant Medical, Beth Israel Deaconess Medical Center, Concept Medical, CPC Clinical Research, Cordis, Elixir Medical, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, Mediasphere Medical, Medtronic, Novartis, Protembis GmbH, RM Global Bioaccess Fund Management, Sanofi US Services, Inc.:Active (exists now) ; Other (please indicate in the box next to the company name):Honorarium: AMA - JAMA Cardiology (Associate Editor), ACC (BOT Member, SC Member CTR Program):Active (exists now) ; Other (please indicate in the box next to the company name):No Fees from: SCAI (Women in Innovations Committee Member), Faculty Cardiovascular Research Foundation (CRF), Women as One (Founding Director):Active (exists now) ; Individual Stocks/Stock Options:Elixir Medical, Stel, ControlRad (spouse):Active (exists now) ; Advisor:Elixir Medical, IQVIA, Medtronic, Medscape/WebMD Global, NovoNordisk:Active (exists now) | Bernard Prendergast: DO NOT have relevant financial relationships | Krithika Loganath: No Answer | marc dweck: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Hottest Clinical Trials in Valvular Heart Disease: Key Insights from Late-Breaking Studies

Saturday, 11/08/2025 , 01:30PM - 02:45PM

Cardiovascular Seminar

More abstracts on this topic:
TAVR vs. SAVR in Low-Risk Aortic Stenosis Patients: 5-Year Outcomes Unveiled for Evolut Low-Risk

Reardon Michael, Forrest John, Popma Jeffrey, Tchetche Didier

Mitral Transcatheter Edge-to-Edge Repair for Moderate Secondary Mitral Regurgitation Among Heart Failure Patients: Results from the EXPANDed Studies

Asgar Anita, Rodriguez Evelio, Tang Gilbert, Chikwe Joanna, Von Bardeleben Ralph Stephan

More abstracts from these authors:
AI biomarkers in the era of multimodality imaging and their role in clinical discovery

Tardif Jean-claude, Dweck Marc

How Low (Risk) Can You Go?: TAVR Should be reserved for high risk patients.

Ouzounian Maral, Thourani Vinod, Prendergast Bernard, Nazif Tamim, Mori Makoto

You have to be authorized to contact abstract author. Please, Login
Not Available